Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 24, 2013JAMA NeurologyOpen Access

High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRichard A. LewisCedars-Sinai Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Richard A. Lewis (2013) studied this question.

synapsesocial.com/papers/6a9632a3086c6a494dbabc51https://doi.org/10.1001/jamaneurol.2013.3178
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disability2012 · 184 citations
  2. 2Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside2005 · 114 citations
  3. 3Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials2007 · 56 citations
  4. 4Challenges in Design of Multicenter Trials2007 · 115 citations